Nuvalent, Inc. |
Director, * Director by deputization, 10%+ Owner |
Class A Common Stock |
8.67M |
$848M |
$97.75 |
Oct 22, 2024 |
Through Deerfield Healthcare Innovations Fund, L.P. |
Nuvalent, Inc. |
Director, * Director by deputization, 10%+ Owner |
Class A Common Stock |
8.67M |
$848M |
$97.75 |
Oct 22, 2024 |
Through Deerfield Private Design Fund IV, L.P. |
AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
11.5M |
$123M |
$10.70 |
Mar 12, 2024 |
Through Deerfield Partners, L.P. |
ARS Pharmaceuticals, Inc. |
10%+ Owner |
Class A Common Stock |
5.26M |
$93.4M |
$17.77 |
Nov 12, 2024 |
Through Deerfield Private Design Fund III, L.P. |
ARS Pharmaceuticals, Inc. |
10%+ Owner |
Class A Common Stock |
5.26M |
$93.4M |
$17.77 |
Nov 12, 2024 |
Through Deerfield Private Design Fund IV, L.P. |
Nuvalent, Inc. |
Director, * Director by deputization, 10%+ Owner |
Class A Common Stock |
650K |
$63.5M |
$97.75 |
Oct 22, 2024 |
Through Deerfield Partners, L.P. |
CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
15.8M |
$54.7M |
$3.46 |
Nov 17, 2023 |
Through Deerfield Partners, L.P. |
Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
6.15M |
$53.8M |
$8.74 |
Feb 16, 2024 |
Through Deerfield Private Design Fund IV, L.P. |
Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
6.15M |
$53.8M |
$8.74 |
Feb 16, 2024 |
Through Deerfield Private Design Fund III, L.P. |
Mirum Pharmaceuticals, Inc. |
* Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.7M |
$47.8M |
$28.04 |
Jun 6, 2022 |
Through Deerfield Private Design Fund IV, L.P. |
Mirum Pharmaceuticals, Inc. |
* Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.54M |
$43.2M |
$28.04 |
Jun 6, 2022 |
Through Deerfield Healthcare Innovations Fund, L.P. |
Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
4.72M |
$41.3M |
$8.74 |
Feb 16, 2024 |
Through Deerfield Healthcare Innovations Fund, L.P. |
Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
4.21M |
$36.8M |
$8.74 |
Feb 16, 2024 |
Through Deerfield Partners, L.P. |
AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
1.71M |
$18.3M |
$10.70 |
Mar 8, 2024 |
Through Deerfield Private Design Fund IV, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Common Stock |
8.94M |
$3.41M |
$0.38 |
Jul 15, 2024 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Common Stock |
8.94M |
$3.41M |
$0.38 |
Jul 15, 2024 |
Through Deerfield Private Design Fund V, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Common Stock |
7.48M |
$3.17M |
$0.42 |
Jun 1, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Common Stock |
1.62M |
$2.53M |
$1.56 |
Jun 16, 2022 |
Through Deerfield Private Design Fund III, L.P. |
Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
834K |
$2.42M |
$2.90 |
Feb 6, 2024 |
Through Deerfield Private Design Fund III, L.P. |
PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
477K |
$1.99M |
$4.17 |
May 10, 2022 |
Through Deerfield Partners, L.P. |
PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
477K |
$1.99M |
$4.17 |
May 10, 2022 |
Through Deerfield Private Design Fund V, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Common Stock |
1.03M |
$1.6M |
$1.56 |
Jun 16, 2022 |
Through Deerfield Partners, L.P. |
Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.14M |
$949K |
$0.83 |
Oct 26, 2021 |
Through Deerfield Partners, L.P. |
Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.14M |
$949K |
$0.83 |
Oct 26, 2021 |
Through Deerfield Private Design Fund V, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.63M |
$689K |
$0.42 |
Jun 1, 2021 |
Through Deerfield Partners, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
1.61M |
$218K |
$0.14 |
Nov 12, 2021 |
Through Deerfield Partners, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
1.61M |
$218K |
$0.14 |
Nov 12, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
20K |
$214K |
$10.70 |
Mar 8, 2024 |
Through Deerfield Management Company, L.P. |
CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
12.1K |
$41.9K |
$3.46 |
Nov 17, 2023 |
Through Deerfield Management Company, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Common Stock |
20.8K |
$32.5K |
$1.56 |
Jun 15, 2023 |
Through Deerfield Management Company, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
85.1K |
$11.6K |
$0.14 |
Nov 12, 2021 |
Through Deerfield Management Company, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
40 |
$5.44 |
$0.14 |
Nov 12, 2021 |
Through DFP Sponsor, LLC |
BiomX Inc. |
Director, *Director by Deputization |
Warrants |
20.2M |
|
|
Jul 9, 2024 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Warrants |
20.2M |
|
|
Jul 9, 2024 |
Through Deerfield Private Design Fund V, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Private Placement Warrants |
3.18M |
|
|
Nov 12, 2021 |
Through DFP Sponsor, LLC |
Frazier Lifesciences Acquisition Corp |
Possible Member of 10% Group, 10%+ Owner |
Class A Ordinary Shares |
2.48M |
|
|
Nov 8, 2022 |
Through Deerfield Partners, L.P. |
Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.16M |
|
|
Dec 30, 2022 |
Through Deerfield Healthcare Innovations Fund, L.P. |
Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1.16M |
|
|
Dec 30, 2022 |
Through Deerfield Private Design Fund III, L.P. |
Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
898K |
|
|
Sep 17, 2024 |
Through Deerfield Partners, L.P. |
Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
898K |
|
|
Sep 17, 2024 |
Through Deerfield Private Design Fund V, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Public Warrants |
625K |
|
|
Nov 12, 2021 |
Through Deerfield Partners, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Public Warrants |
625K |
|
|
Nov 12, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
285K |
|
|
Dec 30, 2022 |
Through Deerfield Partners, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Stock Option (Right to Buy) |
264K |
|
|
Jul 11, 2024 |
Through Deerfield Management Company, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Warrant to Purchase Common Stock |
193K |
|
|
Jun 16, 2022 |
Through Deerfield Private Design Fund III, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
58.9K |
|
|
Nov 12, 2021 |
Through Deerfield Partners, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
58.9K |
|
|
Nov 12, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Series X Non-Voting Convertible Preferred Stock |
48K |
|
|
Jul 15, 2024 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
BiomX Inc. |
Director, *Director by Deputization |
Series X Non-Voting Convertible Preferred Stock |
48K |
|
|
Jul 15, 2024 |
Through Deerfield Private Design Fund V, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
45.6K |
|
|
Nov 12, 2021 |
Through DFP Sponsor, LLC |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Warrant to Purchase Common Stock |
31.1K |
|
|
Jun 16, 2022 |
Through Deerfield Partners, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Stock Option (Right to Buy) |
30K |
|
|
Jun 1, 2021 |
Through Deerfield Management Company, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Stock Option (Right to Buy) |
19.6K |
|
|
Jun 15, 2023 |
Through Deerfield Management Company, L.P. |
Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Stock Option (Right to Buy) |
19K |
|
|
May 29, 2024 |
Through Deerfield Management Company, L.P. |
Nuvalent, Inc. |
Director, * Director by deputization, 10%+ Owner |
Stock Option (Right to Buy) |
3.79K |
|
|
Jun 12, 2024 |
Through Deerfield Management Company, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
1.82K |
|
|
Jun 16, 2022 |
Through Deerfield Private Design Fund III, L.P. |
Acutus Medical, Inc. |
Director, Director by Deputization, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
948 |
|
|
Jun 16, 2022 |
Through Deerfield Partners, L.P. |
Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
Sep 17, 2024 |
Through Deerfield Partners, L.P. |
Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
Sep 17, 2024 |
Through Deerfield Private Design Fund V, L.P. |
CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Restricted Stock Units |
0 |
|
$3.46 |
Nov 17, 2023 |
Through Deerfield Management Company, L.P. |
Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C-2 Preferred Stock |
0 |
|
|
Feb 6, 2024 |
Through Deerfield Private Design Fund III, L.P. |
Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series D Preferred Stock |
0 |
|
|
Feb 6, 2024 |
Through Deerfield Private Design Fund III, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class B Common Stock |
0 |
|
|
Nov 12, 2021 |
Through Deerfield Management Company, L.P. |
Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class B Common Stock |
0 |
|
|
Nov 12, 2021 |
Through DFP Sponsor, LLC |
PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
May 10, 2022 |
Through Deerfield Partners, L.P. |
PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
May 10, 2022 |
Through Deerfield Private Design Fund V, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
6% Convertible Note due 2023 |
0 |
|
|
Jun 1, 2021 |
Through Deerfield Partners, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
6% Convertible Note due 2023 |
0 |
|
|
Jun 1, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
Jun 1, 2021 |
Through Deerfield Private Design Fund IV, L.P. |
Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
Oct 26, 2021 |
Through Deerfield Partners, L.P. |
Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
Oct 26, 2021 |
Through Deerfield Private Design Fund V, L.P. |